Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 4, 2008, Pages

  Huebner, Kyla D ^a   Jassal, Davinder S ^a   Halevy, Orna ^b   Pines, Mark ^c   Anderson, Judy E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c VOLCANI CENTER   (Israel)

Author keywords

smooth muscle actin; Collagen I III; Echocardiography; Hepatocyte growth factor; Ki67

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HALOFUGINONE; KI 67 ANTIGEN; SCATTER FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLLAGENASE DIGESTION METHOD; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; EXERCISE; FIBROSIS; FUNCTIONAL STATUS; GENE; GRIP STRENGTH; HEART; HEART FUNCTION; HEART MUSCLE; MDX GENE; MORBIDITY; MORTALITY; MOUSE; MUSCLE INJURY; MUSCULAR DYSTROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; RESPIRATORY FUNCTION; RUNNING; SKELETAL MUSCLE; TECHNIQUE; TIBIALIS ANTERIOR MUSCLE; TREATMENT PLANNING; TREATMENT RESPONSE;

ACTINS; AGE FACTORS; ANIMALS; CELL PROLIFERATION; COLLAGEN TYPE I; COLLAGEN TYPE III; DIAPHRAGM; DISEASE MODELS, ANIMAL; FIBROSIS; HEART; HEPATOCYTE GROWTH FACTOR; MICE; MICE, INBRED MDX; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; PHYSICAL ENDURANCE; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUADRICEPS MUSCLE; QUINAZOLINONES; RESPIRATORY MECHANICS; RUNNING; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 41749095368     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01253.2007     Document Type: Article

References (67)

1. Alexakis C, Partridge T, Bou-Gharios G. Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am J Physiol Cell Physiol 293: C661-C669, 2007.
2. Anderson JE, Liu L, Kardami E. The effects of hyperthyroidism on muscular dystrophy in the mdx mouse: greater dystrophy in cardiac and soleus muscle. Muscle Nerve 17: 64-73, 1994.
3. Anderson JE, McIntosh LM, Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 19: 1576-1585, 1996.
4. Anderson JE, Weber M, Vargas C. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant 9: 551-564, 2000.
5. Anderson JE, Wozniak AC. Satellite cell activation on fibers: modeling events in vivo - an invited review. Can J Physiol Pharmacol 82: 300-310, 2004.
6. Archer JD, Vargas CC, Anderson JE. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 20: 738-740, 2006.
7. Brown SC, Lucy JA. Dystrophin as a mechanochemical transducer in skeletal muscle. Bioessays 15: 413-419, 1993.
8. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33: 379-386, 2001.
9. Chan YS, Li Y, Foster W, Horaguchi T, Somogyi G, Fu FH, Huard J. Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 95: 771-780, 2003.
10. Chiariello M, Ambrosio G, Cappelli-Bigazzi M, Perrone-Filardi P, Brigante F, Sifola C. A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusion. J Mol Cell Cardiol 18: 283-290, 1986.
11. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 147: 325-338, 1995.
12. Cohn RD, Liang HY, Shetty R, Abraham T, Wagner KR. Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul Disord 17: 290-296, 2007.
13. Coulton GR, Morgan JE, Partridge TA, Sloper JC. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 14: 53-70, 1988.
14. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 63: 21-29, 1990.
15. Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 36: 1-7, 2007.
16. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13: 7-12, 2005.
17. Doevendans PA, Daemen MJ, de Muinck ED, Smits JF. Cardiovascular phenotyping in mice. Cardiovasc Res 39: 34-49, 1998.
18. Finsterer J, Stollberger C, Feichtinger H. Noncompaction in Duchenne muscular dystrophy: frustrated attempt to create a compensatory left ventricle? Cardiology 105: 223-225, 2006.
19. Gal-Levi R, Leshem Y, Aoki S, Nakamura T, Halevy O. Hepatocyte growth factor plays a dual role in regulating skeletal muscle satellite cell proliferation and differentiation. Biochim Biophys Acta 1402: 39-51, 1998.
20. Gazdhar A, Fachinger P, van Leer C, Pierog J, Gugger M, Friis R, Schmid RA, Geiser T. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 292: L529-L536, 2007.
21. Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, Bruck R, Spira G, Nagler A, Kawada N, Yoshizato K, Reinhardt DP, Libermann TA, Pines M. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 328: 153-166, 2007.
22. Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Abu-Amara SN, Geiger B, Genina O, Monsonego-Ornan E, Pines M. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. J Hepatol 40: 269-277, 2004.
23. Goldspink G, Fernandes K, Williams PE, Wells DJ. Age-related changes in collagen gene expression in the muscles of mdx dystrophic and normal mice. Neuromuscul Disord 4: 183-191, 1994.
24. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30: 645-653, 2004.
25. Gosselin LE, Williams JE, Personius K, Farkas GA. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone. Muscle Nerve 35: 208-216, 2007.
26. Hahn A, Bach JR, Delaubier A, Renardel-Irani A, Guillou C, Rideau Y. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch Phys Med Rehabil 78: 1-6, 1997.
27. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156: 766-775, 1997.
28. Herrero-Fresneda I, Torras J, Franquesa M, Vidal A, Cruzado JM, Lloberas N, Fillat C, Grinyo JM. HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 70: 265-274, 2006.
29. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928, 1987.
30. Hoffman EP, Monaco AP, Feener CC, Kunkel LM. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 238: 347-350, 1987.
31. Iwasaki T, Imado T, Kitano S, Sano H. Hepatocyte growth factor ameliorates dermal sclerosis in the tight-skin mouse model of scleroderma. Arthritis Res Ther 8: R161, 2006.
32. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5: 206-210, 1991.
33. Keeling RM, Golumbek PT, Streif EM, Connolly AM. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 35: 43-48, 2007.
34. Leshem Y, Gitelman I, Ponzetto C, Halevy O. Preferential binding of Grb2 or phosphatidylinositol 3-kinase to the met receptor has opposite effects on HGF-induced myoblast proliferation. Exp Cell Res 274: 288-298, 2002.
35. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versushost disease and tight skin mice: effect of halofuginone. J Invest Dermatol 106: 84-88, 1996.
36. Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 11: 23-30, 2002.
37. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59: 2023-2038, 2001.
38. McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. Arthritis Rheum 46: 2748-2761, 2002.
39. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth- factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118: 461-470, 2002.
40. McIntosh LM, Anderson JE. Hypothyroidism prolongs and increases mdx muscle precursor proliferation and delays myotube formation in normal and dystrophic limb muscle. Biochem Cell Biol 73: 181-190, 1995.
41. McNally EM. New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev Med 58: 75-88, 2007.
42. Morrison J, Lu QL, Pastoret C, Partridge T, Bou-Gharios G. T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest 80: 881-891, 2000.
43. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 154: 1082-1086, 1996.
44. Nagler A, Genina O, Lavelin I, Ohana M, Pines M. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am J Obstet Gynecol 180: 558-563, 1999.
45. Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 164: 1776-1780, 2000.
46. Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, Pines M. Halofuginone - an inhibitor of collagen type I synthesis - prevents postoperative formation of abdominal adhesions. Ann Surg 227: 575-582, 1998.
47. Neilan TG, Januzzi JL, Lee-Lewandrowski E, Ton-Nu TT, Yoerger DM, Jassal DS, Lewandrowski KB, Siegel AJ, Marshall JE, Douglas PS, Lawlor D, Picard MH, Wood MJ. Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation 114: 2325-2333, 2006.
48. Neilan TG, Jassal DS, Perez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, Ichinose F, Bayne DB, Halpern EF, Weyman AE, Derumeaux G, Bloch KD, Picard MH, Scherrer-Crosbie M. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 27: 1868-1875, 2006.
49. Pastoret C, Sebille A. Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. Muscle Nerve 18: 1147-1154, 1995.
50. Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 129: 97-105, 1995.
51. Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30: 445-450, 1998.
52. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9: 417-425, 2003.
53. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 14: 491-496, 2004.
54. Ramunddal T, Lindbom M, Omerovic E. Native cardiac reserve predicts survival in acute post infarction heart failure in mice (Abstract). Cardiovasc Ultrasound 5: 46, 2007.
55. + channel. FASEB J 21: 812-822, 2007.
56. Sebag IA, Handschumacher MD, Ichinose F, Morgan JG, Hataishi R, Rodrigues AC, Guerrero JL, Steudel W, Raher MJ, Halpern EF, Derumeaux G, Bloch KD, Picard MH, Scherrer-Crosbie M. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 111: 2611-2616, 2005.
57. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142: 873-881, 1998.
58. Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, Genin O, Iluz M, Kawada N, Yoshizato K, Pines M. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther 6: 570-577, 2007.
59. Skrabek RQ, Anderson JE. Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. Muscle Nerve 24: 192-202, 2001.
60. Stansfield WE, Tang R, Moss NC, Baldwin AS, Willis MS, Selzman CH. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 294: H645-H650, 2008.
61. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352: 536-539, 1991.
62. Sweat F, Puchtler H, Rosenthal SI. Sirius Red F3BA as a stain for connective tissue. Arch Pathol 78: 69-72, 1964.
63. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363, 2002.
64. Von der Mark K. Localization of collagen types in tissues. Int Rev Connect Tissue Res 9: 265-324, 1981.
65. Wess L, Eastwood MA, Wess TJ, Busuttil A, Miller A. Cross linking of collagen is increased in colonic diverticulosis. Gut 37: 91-94, 1995.
66. Wozniak AC, Anderson JE. Nitric oxide-dependence of satellite stem cell activation and quiescence on normal skeletal muscle fibers. Dev Dyn 236: 240-250, 2007.
67. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 284: F349-F357, 2003.